Opko Health Inc (OPK) Actualités

Form 8-K - Current report

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and...

OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025

MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and...

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a...

Form 8-K - Current report

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will...

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and...

NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer

NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference

MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will...

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition...

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a...